All articles tagged with #cagrisema
Eli Lilly's stock rises as Novo Nordisk's new weight-loss drug trial results disappoint, with Lilly gaining investor confidence and analysts rating it a strong buy, while Novo Nordisk faces setbacks and stock decline.
Shares of Novo Nordisk fell up to 3.5% after trial data for its experimental obesity drug CagriSema raised investor concerns about its competitiveness against Eli Lilly, with questions about tolerability and market timing impacting investor confidence amid ongoing competition in the obesity market.
Novo Nordisk's obesity drug CagriSema, which combines Wegovy with a new medicine, showed promising weight loss results in studies, especially at lower doses, suggesting some patients respond well without needing the highest dose. The drug's safety profile is comparable to Wegovy, and the company plans to seek regulatory approval and conduct further studies, including head-to-head comparisons with competitors like Lilly's Zepbound.
Novo Nordisk's obesity drug CagriSema shows similar safety and efficacy to Eli Lilly's Zepbound, with initial weight loss of around 20% over 68 weeks, but the rate of weight loss plateaus, raising questions about its long-term effectiveness.